CD44 and breast carcinoma: On one hand, Foxp3 directly inhibits the activity of the VEGF promoter through a specific forkhead binding motif, which leads to the inhibition of angiogenesis in breast cancer by suppressing the expression of VEGF, consequently downregulating VEGF (49); On the other hand, Foxp3 binds to the promoter of CD44 coding gene to suppress breast cancer metastasis, thereby hindering the progress of breast cancer (50).